By integrating EditCo’s CRISPR-based gene engineering, BrainXell’s specialized iPSC-derived neural cell solutions, and Arctoris’s advanced screening capabilities, we developed TREM2 R47H iPSC-derived microglia for a deeper look at the NLRP3 inflammasome. Early results provided key findings that open the door for new advances in neurodegeneration research.
Conclusions
- CRISPR edited, iPSC-derived human TREM2 R47H microglia show minor morphological and marker expression profiles, and reduced phagocytic activity compared with WT microglia
- TREM2 R47H microglia are hypersensitive to inflammatory stimuli in both general inflammation and chemokine secretion, and NLRP3 inflammasome activation
- Human iPSC-derived microglia are amenable to automated culture protocols for screening
